---
title: "First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295708147.md"
description: "In San Diego on August 12, 2026, First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a biotech company focusing on antibody therapeutics for autoimmune and inflammatory diseases, announced their financial results for the second quarter of 2026 ending on June 30. The company also shared a general business update."
datetime: "2026-08-12T20:29:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295708147.md)
  - [en](https://longbridge.com/en/news/295708147.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295708147.md)
generator: "portal-rs"
---

# First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

In San Diego on August 12, 2026, First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a biotech company focusing on antibody therapeutics for autoimmune and inflammatory diseases, announced their financial results for the second quarter of 2026 ending on June 30. The company also shared a general business update.

### Related Stocks

- [TRAX.US](https://longbridge.com/en/quote/TRAX.US.md)

## Related News & Research

- [SynAct Pharma Expands Resomelagon’s Potential With New Preclinical Inflammation Data](https://longbridge.com/en/news/297303959.md)
- [Generational Group Advises Cantor BioConnect in its Sale to Prairie Capital](https://longbridge.com/en/news/297685099.md)
- [Coya Therapeutics posts September 2026 investor presentation on neurodegeneration pipeline](https://longbridge.com/en/news/297669200.md)
- [Teva Reports Significant Prevention Of Gluten-Induced Damage in New Study](https://longbridge.com/en/news/297800772.md)
- [DWTX: Halneuron shows promise as a scalable, effective CINP therapy with strong Phase 2 results](https://longbridge.com/en/news/297686345.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**